HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium

The HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium, funded by the Bill & Melinda Gates Foundation, is a visionary project designed to accelerate HPV vaccination in low- and middle-income countries (LMICs). We harness collective expertise in policy, access, introduction, implementation, evaluation, and learning. Our overarching aim is to promote equity, program quality, and the rapid expansion of HPV vaccination among girls.

At the global level, our partners include the Bill & Melinda Gates Foundation (BMGF) and global vaccine partners (Gavi, WHO, UNICEF, and CDC), as well as the broader global health community, including HPV advocates/advocacy groups. At the country level, we engage with EPI/MOH, local civil society organizations (CSOs)/NGOs, professional societies, women’s groups, national cancer programs, and other country-level decision-makers, such as the Ministry of Education.

The consortium is poised to deliver substantial benefits and impact to accelerate HPV vaccination among girls through:

• Targeted technical assistance to countries for accelerated HPV vaccine introduction, stakeholder engagement and evidence-based decision-making, and coverage improvement
• Targeted learning, measurement, and evaluation of existing programs and implementation
• Translation of lessons learned into policy, guidelines, and practices
• Extend and complement global coordination of the core HPV vaccine partners

The HAPPI consortium will run through December 2026. The HAPPI Consortium is managed by JSI together along with Clinton Health Access Initiative (CHAI), IVAC at the Johns Hopkins Bloomberg School of Public Health, Jhpiego, and PATH.

Resources

1. Decision-Making Considerations and Drivers of Country-Level Adoption or Switch to a Single-Dose HPV Vaccination Schedule A Global Assessment Brief
2. Decision-Making Considerations and Drivers of Country-Level Adoption or Switch to a Single-Dose HPV Vaccination Schedule: A Global Assessment Technical Report
3. Decision-Making Considerations and Drivers of Country-Level Adoption or Switch to a Single-Dose HPV Vaccination Schedule: A Global Assessment Presentation